Solborn솔본

Solborn posted strong trailing profit on a small market value, but 2025 earnings fell and the stock is down over the past month.

Solborn is a Korean holding company whose main subsidiary makes PACS medical imaging systems, with additional investments in venture capital and overseas listed shares. On trailing twelve-month figures to H1 2026 it reported revenue of ₩125.9B, operating income of ₩28.5B and net income of ₩35.2B, with low debt and a cash balance of ₩20.0B. The share price closed at ₩4,670 on 2026-10-23, near the lower half of its 52-week range of ₩3,155 to ₩5,600.

What stands out

• Trailing net income of ₩35.2B is well above operating income of ₩28.5B, so non-operating gains appear to play a meaningful role; the data does not explain their source.
• Full-year 2025 revenue grew 3.9% to ₩120.7B, but net income fell to ₩20.9B from ₩34.0B in 2024.
• Liabilities-to-equity of 20.3% and borrowings of about ₩0.4B suggest a lightly indebted balance sheet.
• The DCF fair value model gives a base of ₩22,358, but this is a model output from the data pack, not a forecast or recommendation.
• Recent filings are mostly 5%+ holding reports, plus the H1 2026 half-year report filed on 2026-08-14. No news headlines were included in the data.
• Foreign ownership fell slightly to 1.3% and retail investors were net sellers over the last 20 days, while foreign and institutional flows were small net buys.

What to watch

• The next quarterly or annual results, to see whether trailing profit holds up without a large non-operating contribution.
• Further 5%+ holding reports or insider shareholding filings, which may signal changes in major shareholdings.
• Whether the share price stays within its 52-week range, given a 7.7% decline over one month; the data gives no company-specific reason for this.